LGR5 and neoplasm: Should LGR5 also regulate MEK/ERK signalling in CRC cells, this could alter tumour behaviour substantially, particularly during the stages of CRC development where a KRAS mutation (which constitutively activates MAPK signalling) has not yet been accrued.